The Hippo signaling pathway, originally identified in Drosophila melanogaster and later shown to be conserved in mammals, is essential in regulating organ size and maintaining tissue homeostasis. It is now clear that functional inactivation of the Hippo pathway is common in variety of cancers and promotes their development and progression. This suggests re-activation of Hippo pathway activity may prove an effective anti-cancer therapy. Here, we describe two small molecule activators of the Hippo pathway that we have recently uncovered from a focused small-molecule inhibitor screen.
Identifer | oai:union.ndltd.org:bu.edu/oai:open.bu.edu:2144/16121 |
Date | 08 April 2016 |
Creators | Mustaly, Hatim Mustafa |
Source Sets | Boston University |
Language | en_US |
Detected Language | English |
Type | Thesis/Dissertation |
Page generated in 0.0022 seconds